Immunogenicity and Safety of Coadministration of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine and a COVID-19 mRNA Vaccine in Adult s Aged ≥50 Years: A Phase 3, Randomized, Noninferiority Trial
Clinical Infectious Diseases · 2026
DOI: 10.1093/cid/ciag344 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Marc Bonten und 13 weiteren Autor:innen. Beteiligte Einrichtung: Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Vaccines, COVID-19 Vaccines, Viral Fusion Proteins, COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK.
Abstract (Originalsprache)
Background
This trial evaluated coadministration of the AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine (adjuvanted RSVPreF3) and an Omicron XBB.1.5-based coronavirus disease 2019 (COVID-19) mRNA vaccine in ≥50-year-olds.
Methods
This phase 3, open-label, multicenter trial randomized ≥50-year-olds 1:1 to coadministration (Co-Ad group) or sequential administration approximately 1 month apart (Control group) of adjuvanted RSVPreF3 and the COVID-19 mRNA vaccine. Primary objectives were to demonstrate noninferiority of humoral immune responses at 1 month postvaccination in terms of RSV-A, RSV-B, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing titers, with the upper limit of the 95% CI of adjusted geometric mean titer (GMT) group ratios (Control/Co-Ad) ≤1.50. Secondary objectives included assessment of reactogenicity up to 4 days and safety up to 6 months after vaccination.
Results
Overall, 833 participants were vaccinated (Co-Ad: 417; Control: 416). Noninferiority was achieved for RSV-A (GMT ratio: 1.12 [95% CI: .97–1.28]) and RSV-B (GMT ratio: 1.08 [95% CI: .94–1.23]) and marginally missed for SARS-CoV-2 Omicron XBB.1.5 (GMT ratio: 1.31 [95% CI: 1.13–1.51]). Within 4 days postvaccination, the most frequently reported solicited events were administration-site pain, myalgia, and fatigue. Most solicited events were of mild-to-moderate intensity, and the overall median duration was ≤3 days and comparable between groups. Unsolicited and serious adverse events were generally balanced between groups.
Conclusions
Adjuvanted RSVPreF3 coadministered with a COVID-19 mRNA vaccine maintained an acceptable safety profile in ≥50-year-olds. The marginal miss of the noninferiority criterion for SARS-CoV-2 does not suggest clinically relevant interference. Therefore, the results support the coadministration of these vaccines. Clinical Trials Registration Clinical Trials.gov. NCT06374394.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
- European Clinical Research Alliance on Infectious Diseases (ECRAID), Utrecht, The Netherlands.
- Velocity Clinical Research, Omaha, Nebraska, USA.
- Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium.
- Center for Vaccinology, Ghent University and Ghent University Hospital, Ghent, Belgium.
- Preventive Medicine Department, University Hospital Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
ORCID-Profile: Brandon Essink, Nikita Hanning, Isabel Leroux-Roels, Silvina Natalini Martinez, Ghassem Jandari, Sofía Valenciano, Vicky Cárdenas, Marie Van der Wielen
Förderung
- GSK
Zitieren
APA
Bonten, M., Essink, B., Hanning, N., Leroux-Roels, I., Masuet-Aumatell, C., Martinez, S. N., Hailemariam, H. A., Jandari, G., Kwo Ton Ge Jua, P., Servais, C., Valenciano, S., Jastorff, A. M., Cárdenas, V., & Van der Wielen, M. (2026). Immunogenicity and Safety of Coadministration of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine and a COVID-19 mRNA Vaccine in Adult s Aged ≥50 Years: A Phase 3, Randomized, Noninferiority Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag344
Vancouver
Bonten M, Essink B, Hanning N, Leroux-Roels I, Masuet-Aumatell C, Martinez SN, et al. Immunogenicity and Safety of Coadministration of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine and a COVID-19 mRNA Vaccine in Adult s Aged ≥50 Years: A Phase 3, Randomized, Noninferiority Trial. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag344
BibTeX
@article{Bonten2026,
author = {Bonten, Marc and Essink, Brandon and Hanning, Nikita and Leroux-Roels, Isabel and Masuet-Aumatell, Cristina and Martinez, Silvina Natalini and Hailemariam, Hiwot Amare and Jandari, Ghassem and Kwo Ton Ge Jua, Paulia and Servais, Charlotte and Valenciano, Sofía and Jastorff, Archana M and Cárdenas, Vicky and Van der Wielen, Marie},
title = {Immunogenicity and Safety of Coadministration of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine and a COVID-19 mRNA Vaccine in Adult s Aged ≥50 Years: A Phase 3, Randomized, Noninferiority Trial},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag344}
}
EUVIMED